Hostname: page-component-586b7cd67f-r5fsc Total loading time: 0 Render date: 2024-11-28T22:29:43.753Z Has data issue: false hasContentIssue false
  • English
  • Français

Evolution of some liver function markers after treatment in patients with schizophrenia and bipolar disorder

Published online by Cambridge University Press:  19 July 2023

S. Sellami ,
M. Maalej ,
M. Ayadi ,
M. Naifar ,
M. Maalej  and
F. Ayadi
S. Sellami
Affiliation:
Psychiatry “C” department, Hedi Chaker University Hospital PsycLaboratory of Research “Molecular Basis of Human Diseases”, LR19ES13, Faculty of medecine of Sfax
M. Maalej*
Affiliation:
PsycLaboratory of Research “Molecular Basis of Human Diseases”, LR19ES13, Faculty of medecine of Sfax Psychiatry “C” department, Hedi Chaker University Hospital
M. Ayadi
Affiliation:
PsycLaboratory of Research “Molecular Basis of Human Diseases”, LR19ES13, Faculty of medecine of Sfax Laboratory of Biochemistry, Faculty of Medicine of Sfax & Habib Bourguiba Hospital
M. Naifar
Affiliation:
PsycLaboratory of Research “Molecular Basis of Human Diseases”, LR19ES13, Faculty of medecine of Sfax
M. Maalej
Affiliation:
Psychiatry “C” department, Hedi Chaker University Hospital Laboratory of Biochemistry, Faculty of Medicine of Sfax & Habib Bourguiba Hospital, Sfax, Tunisia
F. Ayadi
Affiliation:
PsycLaboratory of Research “Molecular Basis of Human Diseases”, LR19ES13, Faculty of medecine of Sfax
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

The prevalence of alterations of liver function tests in patients with schizophrenia and bipolar disorders is not well known. These alterations are often considered as side effects of medication

Objectives

Our study aimed to evaluate and compare liver function before and after treatment in patients with schizophrenia (SCZ), schizo-affective disorder (SCA) and bipolar disorder (BD).

Methods

This was a prospective study among patients with SCZ, SCA and BD according to DSM-5 criteria. Patients, from the “C” psychiatry department of Hedi Chaker University Hospital in Sfax, were assessed during both acute and remission phases in their illness. The acute phase (T0) assessment was made in drug-free patients from june 2016 to july 2018. As for the remission phase (T1), it was made between november 2019 and march 2020. Blood tests were performed in the Laboratory of Biochemistry at Habib Bourguiba University Hospital in Sfax. Clinical and biological parameters of patients were compared with those of healthy controls. Biological assessment consisted mainly in Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) and Albumine.

Results

Thirty patients were included in our study. Their mean age was 35.83 ± 12.24 years and they were all males. They suffered from SCZ in 33.33% of cases, from SCA in 26.66% of cases and from BD in 40% of cases. Psychoactive substance use was common among 80% of patients. In the remission phase, 90% were polymedicated with use of antipsychotics in 83% of cases and mood stabilisers in 53% of cases. Table 1 shows the evolution of the studied liver function markers in our patients.Table 1:

evolution of some liver function markers in patients

MarkersT0T1p
AST (UI/L)Patients33,22 ± 23,1819,34 ± 4,97<0,001
Controls22,27±6,91<0,05e,b
ALT (UI/L)Patients19,59 ± 13,213,17 ± 11,390,003
Controls20,63±11,08<0,05e,a,b
Albumine (g/l)Patients42,35±4,8647,79±3,18<0,001
Controls46,19±3,95>0,05

a: significant difference between patients with SCZ (T1) and controls; b: significant difference between patients with BD (T1) and controls; e: significant difference between patients (T1) and controls

Conclusions

Our results showed an improvement of liver function in patients with SCZ and BD after treatment. This suggests that liver function alterations are due to these diseases rather than the medication.

Disclosure of Interest

None Declared

Type
Abstract
Information
European Psychiatry , Volume 66 , Special Issue S1: Abstracts of the 31st European Congress of Psychiatry , March 2023 , pp. S922 - S923
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2023. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.